GO
Loading...

Enter multiple symbols separated by commas

Bayer AG

More

  • PARIS, Feb 19- French drugmaker Sanofi on Thursday named Olivier Brandicourt, a Paris- educated doctor and head of Bayer AG's healthcare arm, as its chief executive officer. Brandicourt had been widely tipped to become Sanofi's new boss, a position that opened when Chris Viehbacher was suddenly sacked last year. "Olivier Brandicourt's strong experience...

  • Feb 10- Regeneron Pharmaceuticals Inc reported better-than-expected fourth-quarter sales, driven by surging demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including...

  • Feb 10- Regeneron Pharmaceuticals Inc reported a nearly 14 percent jump in quarterly profit, driven by strong demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including collaboration...

  • ABU DHABI, Jan 20- A plane powered by the sun will attempt an unprecedented flight around the world next month, the project's founders said, seeking to prove that flying is possible without using fossil fuel. Solar Impulse 2 is set to take off from Abu Dhabi with stopovers in India, Myanmar and China before crossing the Pacific Ocean and flying across the United...

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of an anticoagulant drug in a late-stage study, sending the company's shares up 11 percent in premarket trading. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto, developed by...

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • Expirations, drop in hep C drugs hit Merck sales Monday, 27 Oct 2014 | 9:50 AM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.

  • Europe shares close higher on Fed relief, ECB Thursday, 18 Sep 2014 | 11:55 AM ET

    European shares closed higher on Thursday after an important announcement regarding the meetings of the European Central Bank.

  • Bayer plans to float plastics business Thursday, 18 Sep 2014 | 9:54 AM ET

    Germany's largest drugmaker, Bayer, plans to float its plastics business on the stock market and focus on healthcare and crop science.

  • 'Good time' to float plastics business: Bayer CEO   Thursday, 18 Sep 2014 | 7:30 AM ET
    'Good time' to float plastics business: Bayer CEO

    Marijn Dekkers,CEO of Bayer, says now is a "good time" to float the company's plastics business and prefers the IPO route.

  • Merck beats forecasts, as newer drugs offset generics Tuesday, 29 Jul 2014 | 10:39 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.

  • Big lobbying dollars flow in engineered food fight Tuesday, 29 Jul 2014 | 4:29 AM ET
    A researcher takes tissue samples from genetically modified corn plants.

    The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.

  • Merck proud to be a US-based company: CEO Wednesday, 4 Jun 2014 | 8:52 AM ET
    Ken Frazier, president and CEO of Merck.

    But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.

  • Early movers: WMT, GM, DTV, T & more Thursday, 15 May 2014 | 7:42 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Which M&A deal is best for shareholders? Monday, 12 May 2014 | 12:44 AM ET

    Which M&A deal represents the best value for shareholders?

  • Stocks fell Tuesday after American International Group reported a decline in profit.

  • Merck CEO on future M&A and taxes   Tuesday, 6 May 2014 | 11:16 AM ET
    Merck CEO on future M&A and taxes

    Merck CEO Kenneth Frazier speaks with CNBC hours after announcing a blockbuster deal with Bayer.

  • Merck CEO done great job: Cramer   Tuesday, 6 May 2014 | 9:11 AM ET
    Merck CEO done great job: Cramer

    Merck has agreed to sell its consumer care unit to Bayer for $14.2 million. The "Squawk on the Street" news team discuss the $14.2 billion price tag and product development.